ArticleCancer cell2017
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 1 pooled it
12.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 1 synthesis or guideline pooled it, 125 citations in OpenAlex.
- Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review.Cell communication and signaling : CCS · 2019Pooled it
- UBE2N deficiency contributes to MASH development via p62-regulated mitophagy and PANoptosis.Nature metabolism · 2026Article
- Review
- The oncogenic signalosome: SQSTM1/p62 as a master integrator of signaling, metabolism, and autophagy in cancer.Toxicological research · 2026Review
- NADPH-producing enzymes restrict the formation of pancreatic precancerous lesions.Nature metabolism · 2026Article
- Targeting macropinocytosis for cancer therapy.Nature reviews. Cancer · 2026Review
- FLT3-SYK inhibitor and Ixazomib combination impact HOXA and oxidative stress control by β-catenin, SQSTM1 and NRF2 in AML.NPJ precision oncology · 2026Article
- Selective targeting of NRF2-high pancreatic ductal adenocarcinoma with an NQO1-activatable prodrug.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Proteasomal proteolysis in p62 condensates directs tumor suppression or growth depending on their subcellular localization.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Polyphyllin B induces ferroptosis in triple-negative breast cancer by inactivating NRF2.Frontiers in pharmacology · 2026Article
- Long-term SiNPs exposure induced genetic instability and malignant transformation via SQSTM1/p62-mediated autophagy dysfunction in lungs.Materials today. Bio · 2025Article
- Diagnostic value of the correlation between urinary MDM2 and podocyte mitotic catastrophe in diabetic kidney disease.Diabetology & metabolic syndrome · 2025Article
- Self-amplifying NRF2-EZH2 epigenetic loop converts KRAS-initiated progenitors to invasive pancreatic cancer.Nature cancer · 2025Article
- Computational modelling identifies primary mediators of crosstalk between DNA damage and oxidative stress responses.PLoS computational biology · 2025Article
- Lethal clinical outcome and chemotherapy and immunotherapy resistance in patients with urothelial carcinoma with MDM2 amplification or overexpression.Journal for immunotherapy of cancer · 2025Article
- Article
- Expression and Diagnostic Value of Nrf2 and p62 in Cervical Squamous Cell Carcinoma and Intraepithelial Lesions.Cancer management and research · 2025Article
- Inhibition of macrophage inflammasome assembly and pyroptosis with GC-1 ameliorates acute lung injury.Theranostics · 2025Article
- Kelch-like ECH-associated Protein 1/Nuclear Factor Erythroid 2-related Factor 2 Pathway and Its Interplay with Oncogenes in Lung Tumorigenesis.Journal of cancer prevention · 2024Review
- The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and Cancer.Gastroenterology · 2024Review
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 5 institutions in 3 countries.
Jelena TodoricLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA; Department of Laboratory Medicine, Medical University of Vienna, 1090 Vienna, Austria.
Laura AntonucciLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Giuseppe Di CaroLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Ning LiLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Xuefeng WuLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Nikki K LytleDepartments of Pharmacology and Medicine, Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
Debanjan DharLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Sourav BanerjeeDepartment of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Johan B FagmanLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Cecille D BrowneLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Atsushi UmemuraLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA; Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 602-8566 Kyoto, Japan.
Mark A ValasekDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Hannes KesslerLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
David TarinDepartment of Pathology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA.
Michael GogginsDepartments of Medicine (Gastroenterology) and Radiology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD 21287, USA.
Tannishtha ReyaDepartments of Pharmacology and Medicine, Moores Cancer Center, University of California San Diego School of Medicine, La Jolla, CA 92093, USA; Sanford Consortium for Regenerative Medicine, La Jolla, CA 92037, USA.
Maria Diaz-MecoCancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Jorge MoscatCancer Metabolism and Signaling Networks Program, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Michael KarinLaboratory of Gene Regulation and Signal Transduction, Department of Pharmacology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA; Department of Pathology, School of Medicine, University of California San Diego, La Jolla, CA 92093, USA. Electronic address: karinoffice@ucsd.edu.
University of California, San Diego · USDiscovery Institute · USJohns Hopkins University · USSanford Burnham Prebys Medical Discovery Institute · USSanford Consortium for Regenerative Medicine · US
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI Michael Jackson · 1985 to 2026
$107.2MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI LENNON, ANNE MARIE · 1993 to 2022
$54.6MGRADUATE TRAINING IN CELLULAR &MOLECULAR PHARMACOLOGYT32GM007752 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI BROWN, JOAN HELLER, HANDEL, TRACY M · 1985 to 2023
$13.5MMolecular strategies for early detection and targeting of cancerR35CA197699 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Tannishtha Reya · 2015 to 2026
$11.2MVector and Human Acinar CoreP01DK098108 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KARIN, MICHAEL · 2014 to 2018
$8.1MREGULATION OF NFKB AND IKK BY PROINFLAMMATORY STIMULIR01AI043477 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL · 1998 to 2017
$7.4MRole of p62/SQSTM1 in obesity-induced liver cancerR01CA211794 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KARIN, MICHAEL, MOSCAT, JORGE · 2017 to 2021
$3.6MRON Receptor in Pancreatic Cancer Biology and TherapyR01CA155620 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOWY, ANDREW M · 2011 to 2021
$2.9MRole of p62 in metabolic reprograming of the tumor stroma in prostate cancerR01CA218254 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI DIAZ MECO CONDE, MARIA TERESA, METALLO, CHRISTIAN MICHAEL · 2017 to 2021
$2.6MThe p62/MEKK3 complex in mTORC1 activationR01CA192642 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI DIAZ MECO CONDE, MARIA TERESA · 2015 to 2019
$2.2MProtein Kinase Cz targets in Intestinal Cancer Stem CellsR01CA172025 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI MOSCAT, JORGE · 2013 to 2017
$2.2MMusashi-mediated control of pancreatic cancer growth and progressionR01CA186043 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LOWY, ANDREW M, REYA, TANNISHTHA · 2015 to 2019
$2.1MNCI NIH HHS F31 CA206416NCI NIH HHS P30 CA030199NCI NIH HHS P50 CA062924NCI NIH HHS R01 CA132847NCI NIH HHS R01 CA134530NCI NIH HHS R01 CA155620NCI NIH HHS R01 CA163798NCI NIH HHS R01 CA172025NCI NIH HHS R01 CA186043NCI NIH HHS R01 CA192642NCI NIH HHS R01 CA211794NCI NIH HHS R01 CA218254NCI NIH HHS R03 CA167120NCI NIH HHS R35 CA197699NIAID NIH HHS R01 AI043477NIDDK NIH HHS P01 DK098108NIGMS NIH HHS T32 GM007752
Abstract
Despite expression of oncogenic KRAS, premalignant pancreatic intraepithelial neoplasia 1 (PanIN1) lesions rarely become fully malignant pancreatic ductal adenocarcinoma (PDAC). The molecular mechanisms through which established risk factors, such as chronic pancreatitis, acinar cell damage, and/or defective autophagy increase the likelihood of PDAC development are poorly understood. We show that accumulation of the autophagy substrate p62/SQSTM1 in stressed Kras
Indexed as
Acinar CellsAdenocarcinoma in SituAnimalsCarcinoma, Pancreatic DuctalDisease ProgressionHeterograftsHumansMiceMice, Inbred C57BLMice, Inbred NODMice, SCIDNF-E2-Related Factor 2Pancreatic NeoplasmsProto-Oncogene Proteins c-mdm2Signal TransductionMDM2 protein, humanNFE2L2 protein, humanNF-E2-Related Factor 2Proto-Oncogene Proteins c-mdm2acinar cell reprogrammingIKKαimpaired autophagyMDM2NRF2p62pancreatic ductal adenocarcinoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.